The ME Association, a national charity based in Gawcott, Bucks, has announced its investment in a major clinical trial in Canada to study the effects of low-dose naltrexone (LDN) on ME, chronic fatigue syndrome (CFS) and Long Covid.
The trial, led by Dr. Luis Nacul at the University of British Columbia, will investigate whether LDN can alleviate symptoms like fatigue, pain, and sleep disturbances while reducing inflammation.
With no current cure for ME/CFS or Long Covid, the study aims to provide crucial evidence on LDN’s potential benefits. If successful, it could pave the way for wider use of the drug in the UK. Dr. Charles Shepherd, the ME Association’s medical advisor, emphasized the urgent need for effective treatments, highlighting the significant impact these conditions have on individuals and healthcare systems.
The double-blind, placebo-controlled trial is set to conclude by December 2025, with results expected in early 2026.
The ME Association in Bucks hopes this research will contribute to better treatment options for those suffering from these debilitating conditions.
Risborough Rangers Stadium Break-In Threatens Memorial Fundraising Efforts
Local author publishes second novel
Buckinghamshire schools take part in Dragons' Den-style green technology challenge
Big Give Boost for Hospice at Home Care
Consultation on Churchway Speed Limit Reduction in Haddenham
Leader of Buckinghamshire Council responds to national Budget
Shoppers get a festive lift with Boxing Day train route
1,300 Arrests as TVP Target Town-Centre Crime
